FB   160.76 (+2.53%)
MSFT   157.06 (+4.92%)
GOOGL   1,132.75 (+2.03%)
AMZN   1,964.86 (+3.41%)
NVDA   260.97 (+3.26%)
MU   44.88 (+3.22%)
TSLA   500.01 (-2.79%)
AMD   48.13 (+3.33%)
NFLX   370.11 (+3.64%)
GILD   74.35 (+2.06%)
FB   160.76 (+2.53%)
MSFT   157.06 (+4.92%)
GOOGL   1,132.75 (+2.03%)
AMZN   1,964.86 (+3.41%)
NVDA   260.97 (+3.26%)
MU   44.88 (+3.22%)
TSLA   500.01 (-2.79%)
AMD   48.13 (+3.33%)
NFLX   370.11 (+3.64%)
GILD   74.35 (+2.06%)
FB   160.76 (+2.53%)
MSFT   157.06 (+4.92%)
GOOGL   1,132.75 (+2.03%)
AMZN   1,964.86 (+3.41%)
NVDA   260.97 (+3.26%)
MU   44.88 (+3.22%)
TSLA   500.01 (-2.79%)
AMD   48.13 (+3.33%)
NFLX   370.11 (+3.64%)
GILD   74.35 (+2.06%)
FB   160.76 (+2.53%)
MSFT   157.06 (+4.92%)
GOOGL   1,132.75 (+2.03%)
AMZN   1,964.86 (+3.41%)
NVDA   260.97 (+3.26%)
MU   44.88 (+3.22%)
TSLA   500.01 (-2.79%)
AMD   48.13 (+3.33%)
NFLX   370.11 (+3.64%)
GILD   74.35 (+2.06%)
Log in

NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

$7.41
+0.03 (+0.41 %)
(As of 03/30/2020 11:21 AM ET)
Today's Range
$7.29
Now: $7.41
$7.52
50-Day Range
$5.35
MA: $6.57
$7.93
52-Week Range
$3.24
Now: $7.41
$8.92
Volume6,623 shs
Average Volume2.28 million shs
Market Capitalization$285.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Read More
Kala Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.07 million
Book Value$0.86 per share

Profitability

Net Income$-94,350,000.00
Net Margins-1,553.29%

Miscellaneous

Employees130
Market Cap$285.80 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.


Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

How has Kala Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KALA shares have decreased by 2.9% and is now trading at $7.41. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kala Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kala Pharmaceuticals.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Kala Pharmaceuticals.

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals Inc (NASDAQ:KALA) posted its quarterly earnings results on Wednesday, February, 12th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.03. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $2.92 million. Kala Pharmaceuticals had a negative net margin of 1,553.29% and a negative return on equity of 173.83%. View Kala Pharmaceuticals' earnings history.

What price target have analysts set for KALA?

4 brokerages have issued 1 year target prices for Kala Pharmaceuticals' stock. Their forecasts range from $13.00 to $34.00. On average, they expect Kala Pharmaceuticals' stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price. View analysts' price targets for Kala Pharmaceuticals.

Has Kala Pharmaceuticals been receiving favorable news coverage?

Headlines about KALA stock have been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutKala Pharmaceuticals.

Are investors shorting Kala Pharmaceuticals?

Kala Pharmaceuticals saw a increase in short interest in March. As of March 13th, there was short interest totaling 7,001,400 shares, an increase of 28.2% from the February 27th total of 5,460,000 shares. Based on an average daily volume of 2,339,000 shares, the short-interest ratio is currently 3.0 days. Approximately 23.5% of the company's shares are short sold. View Kala Pharmaceuticals' Current Options Chain.

Who are some of Kala Pharmaceuticals' key competitors?

What other stocks do shareholders of Kala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Amarin (AMRN), Bristol-Myers Squibb (BMY), Exelixis (EXEL), NVIDIA (NVDA), SCYNEXIS (SCYX), AbbVie (ABBV), Agile Therapeutics (AGRX), Gilead Sciences (GILD), Micron Technology (MU) and Sorrento Therapeutics (SRNE).

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the following people:
  • Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 53)
  • Mr. Todd Bazemore, Chief Operating Officer (Age 49)
  • Dr. Kim Brazzell, Chief Medical Officer (Age 66)
  • Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 44)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Banco Bilbao Vizcaya Argentaria S.A. (4.06%), Sofinnova Investments Inc. (1.92%), Polaris Venture Management Co. V L.L.C. (1.64%), Alyeska Investment Group L.P. (1.27%), State Street Corp (1.05%) and Geode Capital Management LLC (0.92%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah and Todd Bazemore. View institutional ownership trends for Kala Pharmaceuticals.

Which major investors are selling Kala Pharmaceuticals stock?

KALA stock was sold by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Bank of America Corp DE, Alambic Investment Management L.P., and Group One Trading L.P.. View insider buying and selling activity for Kala Pharmaceuticals.

Which major investors are buying Kala Pharmaceuticals stock?

KALA stock was bought by a variety of institutional investors in the last quarter, including Banco Bilbao Vizcaya Argentaria S.A., Sofinnova Investments Inc., Nuveen Asset Management LLC, Wedbush Securities Inc., State Street Corp, Alyeska Investment Group L.P., Geode Capital Management LLC, and Virtu Financial LLC. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah, and Todd Bazemore. View insider buying and selling activity for Kala Pharmaceuticals.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $7.41.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $285.80 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe. View additional information about Kala Pharmaceuticals.

What is Kala Pharmaceuticals' official website?

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]


MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  485
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel